Elutia (ELUT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$12.1M

Revenue (quarter)

$2.4M

Revenue growth (year over year)

−11.65%

Gross profit (trailing twelve months)

$7.0M

Gross margin

57.76%

Net income (trailing twelve months)

$51.8M

Net income (quarter)

−$7.6M

Net income growth (year over year)

+20.44%

Net margin

426.90%

Return on equity

—

EPS (trailing twelve months)

$1.28

Book value per share

$0.36

P/E (trailing twelve months)

0.59

Price to book

2.22

Debt to assets

63.93%

Payout ratio

—

Dividend yield

—

Company profile

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

• Is Elutia (ELUT) profitable?

  Yes. Elutia earned $51.8M in net income over the trailing twelve months, a net margin of 426.90%.

• How much revenue does Elutia (ELUT) make?

  Elutia generated $12.1M in revenue over the trailing twelve months, down 11.65% year over year.

• What is ELUT's P/E ratio?

  Elutia trades at 0.6 times trailing twelve-month earnings, on an EPS of $1.28.

• How do I buy stock in Elutia (ELUT)?

  ELUT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.